Hi ,

Synthetic biology is rewriting the rules of what’s possible, and this week’s breakthroughs prove it. An AI trained on the DNA of 100,000 species is accelerating genome design, a century-old tuberculosis vaccine might finally get an mRNA upgrade, and a new antibody-toxin combo is tricking tumors into exposing themselves to the immune system. Meanwhile, biotech funding is flowing fast—Cambium raises $18.5M for sustainable materials, Solis Agrosciences secures Series A funding, and Bluebird Bio is set for acquisition. And if you're keeping an eye on the market, don’t miss our March 27 webinar, where experts will break down how the industry is projected to skyrocket from $19B to $62B by 2029. Plus, nominations are now open for the SynBioBeta Global Synthetic Biology Awards—who do you think is shaping the future of this field? Finally, Ticket prices are set to increase this Friday, so get your ticket today and save some green!

Enjoy your week!

John Cumbers with Drew Berry - SynBioBeta 2024 Biodesign Industry Award Winner

The nominations for this year's SynBioBeta Global Synthetic Biology Awards are now open! Submit your recommendations for individuals or organizations that you believe deserve to be recognized for their outstanding contributions to the field of synthetic biology.

This year’s categories: Lifetime Achievement Award, Pioneer Award, Impact Award, and Rising Star Award.

Check Out Our Latest Sponsors and Exhibitors for SynBioBeta 2025!

Venture Capital Firms and Investment Companies Who've Recently Registered

Forbion, William Blair, Perella Weinberg Partners, Sofinnova Partners, AIX Ventures, Starlight Ventures, Breakout Ventures, Grey Heron, Germin8 Ventures, Pillar Infrastructure, CSC Leasing Company, X, The Moonshot Company, Lewis & Clark AgriFood, Tin Alley Ventures, VIB, Bioeconomy Capital, Allozymes, SRI International, IARPA, and Evonik.

Join us on March 27 for an illuminating webinar where SynBioBeta’s CEO John Cumbers and Futurity Systems’ CTO Mark Bünger will dive into the fast-growing world of synthetic biology. As we project a growth from $19B in 2024 to $62B by 2029, they'll reveal key findings from the 2025 SynBioBeta Investor Report. Discover trends and data essential for anyone aiming to lead in sectors like healthcare, agriculture, consumer products, and more. Register for free now to get early access to the full report and transform your strategic insights into action!

Decentralized Platforms Upending How Synthetic Biology is Done

Decentralized science platforms are allowing researchers to fund, conduct, and publish their research over the blockchain.

Evo2: One Bio-AI Model to Rule Them All

This Arc Institute–NVIDIA collaboration, called Evo 2, is a colossal AI model trained on the DNA of over 100,000 species, deftly spotting disease mutations and even crafting new genomes.

The Antibody That Tricks Tumors into Exposing Themselves

Scientists have developed an antibody-toxin conjugate (ATC) that forces the immune system to recognize and attack tumors, offering a new approach to cancer treatment.